Use of a compound of formula (I) or a 3-enol C1 to 4 alkanoate ester thereof in the manufacture of a medicament for the treatment of a hormone dependant condition by modulation of the oestrogen receptor beta (ERbeta) wherein R1 R2 R5 and R6 are the same or different and each is hydrogen or C1 to 4 alkyl; R3 is hydrogen C1 to 4 alkyl C1 to 4 alkenyl or C1 to 4 alkynyl; R4 is hydroxy C1 to 4 alkanoyloxy a group of formula (II) or (III) wherein R7 is (CH2)n where n is an integer of from 0 to 4 R8 i...

The present invention relates to novel therapeutic indications for trilostane or for a derivative thereof as an antidepressant and as an anxiolytic. In particular the invention shows that trilostane has a potentiated (increased) antidepressant effect in patients suffering from Alzheimer’s disease. In addition the elderly population is particularly targeted by this invention.

The present invention relates to a method for the preparation of trilostane from (4α5α17β)-45-epoxyandrost-2-eno(23-d)isoxazol-17-o1 as a precursor compound the method comprising the steps of a) dissolving the precursor compound in methanol; b) treating the precursor compound with a base to effect cleavage of the (23-d) isoxazole ring of the precursor compound; c) adding acid and water to the product of step b) to obtain a precipitate of Trilostanc; and d) isolating the precipitate of Trilostane...

A method for the preparation of trilostane from (4 a 5 a 17 b )-45-epoxyandrost-2-eno(23-d)isoxazol-17-ol without the need for recrystallisation comprising a) dissolving the precursor in methanol; b) treating the precursor with a base to cleave the (23-d)isoxazole ring; c) adding acid and water to the product of step b) to precipitate the trilostane; and d) isolating the trilostane precipitate. Preferred bases are alkali metal hydroxides or alkoxides particularly sodium or potassium hydrox...

An anti-oestrogen (which is a competitive ligand of the oestrogen receptor b (ERb)) and one of trilostane or keto-trilostane is used in the manufacture of a medicament for the treatment of an oestrogen dependent cancer or tumour. A product contains one or more anti-oestrogens which is a competitive ligand of the oestrogen receptor b (ERb) and one of trilostane or keto-trilostane formulated for combined use in the treatment of an oestrogen dependent cancer or tumour.